SANOFI-AVENTIS (EPA:SAN) | WebDisclosure

Basculer en Français

10066	Companies
205772	Keywords
136030	Articles
109102	Press releases

Home
Companies
SANOFI-AVENTIS

PRESS RELEASE

published on 12/07/2024 at 17:30, 1 year 3 months ago

Press Release: ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP
Positive phase 3 study shows rilzabrutinib benefits in ITP patients. Results include platelet response, reduced bleeding, improved quality of life. Safety and efficacy highlighted

Phase 3 Study Rilzabrutinib ITP BTK Inhibitor Patient Benefit
BRIEF

published on 12/06/2024 at 07:35, 1 year 3 months ago

Sanofi Publishes Revised Financial Statements Excluding Opella

Financial Statements Biopharma Sanofi 2024 Results Opella
BRIEF

published on 12/06/2024 at 07:35, 1 year 3 months ago

Sanofi publie ses états financiers révisés excluant Opella

États Financiers Résultats 2024 Biopharma Sanofi Opella
PRESS RELEASE

published on 12/06/2024 at 07:30, 1 year 3 months ago

Press Release: Availability of the revised financial statements for Sanofi excluding Opella
Sanofi releases revised financial statements excluding Opella. The adjustments classify Opella as discontinued operations, aligning with Sanofi's transition to a biopharma company. Q4 2024 results expected on Jan 30, 2025

Sanofi Discontinued Operations Opella Revised Financial Statements Biopharma Company
PRESS RELEASE

published on 12/06/2024 at 07:30, 1 year 3 months ago

Communiqué de presse : Mise en ligne des états financiers révisés de Sanofi hors Opella
Publication des états financiers révisés de Sanofi, hors Opella, suite à la cession de 50% à CD&R. Sanofi se recentre sur la biopharmacie et l'innovation

Cession États Financiers Sanofi Opella Biopharmacie
PRESS RELEASE

published on 10/25/2024 at 07:30, 1 year 4 months ago

Press Release: Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated vaccine sales; 2024 business EPS guidance raised due to strong business performance
PRESS RELEASE

published on 10/25/2024 at 07:30, 1 year 4 months ago

Communiqué de presse : T3 2024 : Croissance des ventes de 15,7% soutenue par une séquence des ventes de vaccins plus favorable qu’anticipée; Sanofi relève ses perspectives de BNPA des activités 2024 suite à la forte performance
BRIEF

published on 10/24/2024 at 14:05, 1 year 4 months ago

Positive Phase 3 Data for Dupixent in Chronic Spontaneous Urticaria Released

Dupixent Chronic Spontaneous Urticaria Phase 3 Data ACAAI Presentation Treatment Innovation
BRIEF

published on 10/24/2024 at 14:05, 1 year 4 months ago

Publication de données positives de phase 3 pour Dupixent dans l'urticaire chronique spontanée

Dupixent Urticaire Chronique Spontanée Données De La Phase 3 Présentation De L'ACAAI Innovation En Matière De Traitement
PRESS RELEASE

published on 10/24/2024 at 14:00, 1 year 4 months ago

Press Release: Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI
Dupixent phase 3 data in chronic spontaneous urticaria presented at ACAAI shows reduced itch and hive activity, potential new treatment for CSU patients

Dupixent Chronic Spontaneous Urticaria ACAAI Phase 3 Data Targeted Treatment

Accesswire

Published on 03/23/2026 at 14:05, 2 hours 35 minutes ago

Wellgistics Health Inc. Signs $105,000,000 Letter of Intent to Evaluate Potential Acquisition of Neuritek Therapeutics, Inc. which is Pioneering Innovative Therapies for Neurological and Psychiatric Disorders
Published on 03/23/2026 at 14:00, 2 hours 40 minutes ago

BlackBerry AtHoc Advances Command Center for Faster Response and Tighter Control During Critical Operations
Published on 03/23/2026 at 13:05, 3 hours 35 minutes ago

SouthGobi Announces Disclosable and Connected Transaction Deferral of Payment Obligations Under Convertible Debenture and Amended and Restated Cooperation Agreement
Published on 03/23/2026 at 12:32, 4 hours 8 minutes ago

Sinopec Announced 2025 Annual Results Annual Payout Ratio Reached 81%
Published on 03/23/2026 at 12:30, 4 hours 10 minutes ago

Digi Power X to Announce 2025 Year End Financial Results on March 31st

View all ACCESSWIRE

EQS Group

Published on 03/23/2026 at 16:20, 19 minutes ago

Switzerland Remove Niels Troost from Sanctions
Published on 03/23/2026 at 15:05, 1 hour 34 minutes ago

Heidrick & Struggles Launches Heidrick Immersive, an AI-Enhanced Platform for Observing Leadership in Motion
Published on 03/23/2026 at 14:41, 1 hour 58 minutes ago

CEWE increases dividend for 17 consecutive years
Published on 03/23/2026 at 14:30, 2 hours 9 minutes ago

Solvias Earns EcoVadis Bronze Medal, Ranking in Top 35% of Companies for Sustainability Performance
Published on 03/23/2026 at 14:30, 2 hours 10 minutes ago

Belvilla Expands in Germany with Hambachtal Holiday Park in Oberhambach

Les Echos

Published on 03/23/2026 at 08:10, 8 hours 30 minutes ago

Entrée en négociations exclusives de cession de la participation dans Winncare
Published on 03/20/2026 at 19:00, 2 days 21 hours ago

AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 19:00, 2 days 21 hours ago

AXA - Modalités de mise à disposition ou de consultation des informations relatives à l’Assemblée Générale du 30 avril 2026
Published on 03/20/2026 at 18:15, 2 days 22 hours ago

Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 18:15, 2 days 22 hours ago

Mise à disposition du Document d’Enregistrement Universel 2025 d’AXA

View all LES ECHOS COMFI WIRE